Idiopathic pulmonary fibrosis in infants

Osika, E.; Muller, M H; Boccon‐Gibod, Liliane; Fauroux, Brigitte; Sardet, A; Grosskopf, C.; Couvreur, J; Tournier, G; Clément, Annick

doi:10.1002/(sici)1099-0496(199701)23:1<49::aid-ppul6>3.0.co;2-k

Cited by 55 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As indicated above, the choice between steroids and hydroxychloroquine was highly centre-dependent [5,6,10,11]. The diversity of the diagnoses and the heterogeneity of the recruited population did not allow information to be drawn on which therapeutic strategy would be more beneficial for a given pathological situation.…”

Section: Commentsmentioning

confidence: 99%

Task force on chronic interstitial lung disease in immunocompetent children

Clément

2004

European Respiratory Journal

161

163

View full text Add to dashboard Cite

Chronic interstitial lung diseases in children represent a heterogeneous group of disorders of both known and unknown causes that share common histological features. Despite many efforts these diseases continue to present clinical management dilemmas, principally because of their rare frequency that limits considerably the possibilities of collecting enough cases for clinical and research studies. Through a Task Force conducted by the European Respiratory Society, which comprised respiratory physicians and basic scientists from across Europe, 185 cases of interstitial lung diseases in immunocompetent children were collected and reviewed. The present report provides important clinically-relevant information on the current approach to diagnosis and management of chronic interstitial lung diseases in children. In addition, recommendations for the management of paediatric interstitial lung diseases, as well as new insights into interstitial lung diseases pathophysiology during childhood are discussed

show abstract

Section: Commentsmentioning

confidence: 99%

Task force on chronic interstitial lung disease in immunocompetent children

Clément

2004

European Respiratory Journal

161

163

View full text Add to dashboard Cite

show abstract

“…So far no association with EBV infection has been documented [2,22,23]. The chronic ILD observed in the current patients obviously did not progress into clearcut CFA.…”

Section: Discussionmentioning

confidence: 46%

“…IPF in infants is a disease with variable prognosis and response to treatment; mortality rate has been reported to range 30±90% [22,23]. So far no association with EBV infection has been documented [2,22,23].…”

Section: Discussionmentioning

confidence: 99%

Chronic interstitial lung disease due to Epstein-Barr virus infection in two infants

Pfleger¹,

Eber²,

Popper³

et al. 2000

Eur Respir J

View full text Add to dashboard Cite

This case study reports on two infants, 5 and 6 months of age, respectively, with chronic interstitial lung disease who presented with failure to thrive, tachypnoea, rales and mild hypoxaemia.Epstein-Barr virus (EBV) was detected by in situ hybridization in lung biopsy specimens and by EBV-deoxyribonucleic acid-polymerase chain reaction (PCR) in bronchoalveolar lavage (BAL) fluid in one patient and by in situ hybridization and PCR analysis in BAL fluid in the second patient. There was serological evidence of immunoglobulin G antibodies to EBV capsid antigen by indirect immunofluorescence in both patients.After 7 months of respiratory symptoms one patient was successfully treated with a 10 day course of intravenous ganciclovir followed by oral acyclovir for 20 days. The other patient became symptom free after 3.5 months of respiratory symptoms, without any specific antiviral medication. During a follow-up of 2 and 1.5 yrs, respectively, both infants remained symptom free and showed normal physical development. Eur Respir J 2000; 15: 803±806.

show abstract

“…Table 39 summarizes the 11 reports of using an antimalarial agent for sarcoidosis [554][555][556][557][558][559][560][561][562][563] along with one series of use of these drugs for pulmonary fi brosis. 564 3.7.1.1 Toxicity-Chloroquine toxicity is most frequently encountered when parenteral routes are used to treat comatose patients with malaria. Cardiovascular effects may progress through vasodilation, hypotension, suppressed myocardial function, cardiac arrhythmia, and cardiac arrest .…”

Section: Information For Patientsmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

Idiopathic pulmonary fibrosis in infants

Cited by 55 publications

References 21 publications

Task force on chronic interstitial lung disease in immunocompetent children

Task force on chronic interstitial lung disease in immunocompetent children

Chronic interstitial lung disease due to Epstein-Barr virus infection in two infants

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About